Sandbox Reserved 1719
From Proteopedia
| Line 111: | Line 111: | ||
The conformations of the G-proteins vary based on their association with a particular membrane receptor due to interactions between the amino acids in the N-terminus of the α subunit and the C-terminus of the receptor.<ref name="Kamato"/> | The conformations of the G-proteins vary based on their association with a particular membrane receptor due to interactions between the amino acids in the N-terminus of the α subunit and the C-terminus of the receptor.<ref name="Kamato"/> | ||
[[Image:Mast cell mechanism.png|500px|right|thumb|'''Figure 9.''' Cellular response of mast cell upon activation of MRGPRX2.]] | [[Image:Mast cell mechanism.png|500px|right|thumb|'''Figure 9.''' Cellular response of mast cell upon activation of MRGPRX2.]] | ||
| + | |||
| + | |||
Revision as of 17:42, 18 April 2022
Human Itch G-Coupled Protein Receptors
IntroductionG protein-coupled receptors (GPCRs) are the largest class of integral membrane proteins divided into five families; the rhodopsin family (class A), the secretin family (class B), the glutamate family (class C), the frizzled/taste family (class F), and the adhesion family.[1][2].[1] GPCRs promote signal transduction activated by a variety of stimuli by undergoing a transmembrane domain conformational change once ligand binding to the N-terminus occurs. This allows for the transduction of a signal to a coupled, heterotrimeric G protein, which then dictates whether an intracellular signaling pathway will be initiated or inhibited. [1][2] Human Itch G-coupled protein receptors (GPCRs), or Mast cell-related GPCRs (MRGPRX), have been identified as pruritogenic receptors and are found in human sensory neurons, specifically in the connective tissue mast cells and dorsal root ganglia in humans.[3] They are classified as class A GPCRs, however, MRGPRX receptors respond to a diverse number of agonists, antagonists, and inverse agonists some of which are not typical ligands of class A receptors. MRGPRX receptors are involved in host defense, pseudo-allergic reactions, non-histaminergic itch, periodontitis, neurogenic inflammation, and inflammatory pain.[3] The determination of the first structures of a ligand-activated GPCR was achieved by Robert J. Lefkowitz and Brian K. Kobilka which won them the 2012 Nobel Prize in Chemistry. They also successfully captured images of the first activated GPCR in a complex with a G protein. See Nobel Prizes for 3D Molecular Structure. Related EnzymesAmong Human Itch GPCRs, MRGPRX2 is a class A GPCR that regulates mast cell degranulation and itch-related hypersensitivity reactions.[4][5] MRGPRX2 is also a target of morphinan alkaloids, like morphine, codeine, and dextromethorphan.[4][5] MRGPRX2 couples to nearly all G-protein families and subtypes with robust coupling to Gq and Gi families.[4][5] is another sub-group of the MRGPRX family, which mediates cholestatic itch and is a target of nateglinide drugs.[4][5] MRGPRX4 also couples to Gq and Gi similar to MRGPRX2. Structure OverviewThe receptor Ligand binding occurs at the N-terminus in the extracellular domain and is composed of two binding sub-pockets.[4] The intracellular domain consists of helix VII and a C-terminal sequence, which binds the G-protein and promotes downstream signaling.[4] Ligand Binding SiteIn , the ligand binding pocket is located in the N-terminus of the transmembrane domain and consists of two sub-pockets that differ in physical and chemical properties (Figure 2) that allows for various ligand interactions. Unlike most class A GPCRs, the ligand binding site of MRGPRX2 is closer to the surface of the membrane due to the absence and alterations in conserved class A GPCR motifs and structures.
   Sub-pocket 1is a small, shallow pocket formed by TM3, TM6, and ECL2.[4] Ligand binding is mediated by two key residues on the MRGPRX2 protein within the binding site: Glu164 and Asp184.[4] The strong charge interactions of these two residues create a highly negatively electrostatic interaction crucial for binding cationic ligands, namely those containing arginine or lysine as shown in Figure 3.[4].
Sub-pocket 2is formed by TM1, TM2, TM6, and TM7.[4] This binding sub-pocket is much broader and allows for the binding of larger structures (Figure 3).[4] The key residues involved are Trp243 and Phe170 that contributes to the high hydrophobicity of the binding pocket.[4] The hydrophobicity of this binding pocket accounts for the large electrostatic difference observed between the two sub pockets demonstrated in Figure 2.
Ligand interactions
 Differences to most class A GPCRsThe unique characteristics of in comparison to class A GPCRs provides an explanation for the differences in ligand interactions. These differences in intermolecular interactions and structural motifs contribute to the surface level ligand binding in MRGPRX2, whereas the typical ligand interaction occurs deep within the helices in class A GPCRs.
 Toggle switchThe conserved of class A GPCRs acts to activate or inhibit the transduction of the signaling cascade. Typical class A GPCRs contain the conserved ‘toggle switch’ Trp336. In MRGPRX2, this residue is replaced by . [4] By substituting the larger Trp residue with a smaller Gly residue, TM6 is shifted closer to TM3 on the extracellular side of the membrane and contributes to the more tightly packed and shallow binding pocket as compared to other canonical structures. The occluded binding pocket contributes the surface level binding depicted in Figure 6, and allows for a greater variety of ligands interactions with MRGPRX2 as compared to other class A GPCRs, such as 5-HT2AR, A2AR, and β2AR.[4] PIF/LLF motifThe majority of class A GPCRs contain a conserved at the TM3-TM6 interface. [4] Canonically, the conserved PIF motif consists of a Pro, Ile, and Phe that transduce the signal produce by ligand binding through the TMD within conserved distances.[4][8] In MRGPRX2, the PIF motif is changed to a , in which the residues are not conserved at specific positions in the amino acid sequence, but instead are conserved at distances that allow them to interact.[4] The residues that make up TM5 have shifted down two residues making Leu194 analogous to the position of the Pro in other GPCRs. Compared with other structures, such as 5-HT2AR, A2AR, and β2AR, the TM6 helix of MRGPRX2 is closer to the TM3 helix due to the shift in residues, which accounts for the tighter packing of the transmembrane domain helices [4], thereby contributing to surface level ligand interactions. DRY/ERC motifThe majority of class A GPCRs have a conserved E/DRY motif that is responsible for creating salt bridges that maintain the inactive conformation of the receptor until ligand binding.[4] In contrast, Figure 7 shows MRGPRX2 containing an in place of the E/DRY motif, which replaces Tyr174 with Cys128.[4] This replacement alters the spatial organization of the helices due to the replacement of the larger Tyr residue with the smaller Cys residue, thereby condensing the helices.[4] The condensed spatial organization in MRGPRX2 accounts for the less significant change once a ligand binds to the receptor.[4]  Disulfide bondsIn general, class A GPCRs have a between TM3 and ECL2.[4] In contrast, Figure 8 shows the location MRGPRX2 between Cys168 of TM4 and Cys180 of TM5, which structurally flips ECL2 to the top of TM4 and TM5.[4] This creates the wide ligand-binding surface of MRGPRX2 that contributes to surface level binding which allows diverse ligand interactions.[4]  Sodium binding siteThe sodium binding site conserved in class A GPCRs allosterically modulates the stabilization of the GPCR's inactive state. The of MRGPRX2 contains the conserved Asp75, however, the conserved Ser116 on TM3 seen in class A GPCRs is replaced by Gly116.[4] The presence of Gly as opposed to the polar Ser contributes to a lack of polar character in addition to decreasing the size of the binding pocket. The sodium pocket generally serves as an allosteric binding pocket for sodium. Both factors thereby limit the binding of sodium ions to the sodium binding site in MRGPRX2. MechanismG-proteins, when paired with a GPCR, assist in signal transduction.[9][10] G-proteins are heterotrimeric GTPases composed of three subunits: . The α subunit acts as the main signal mediator and contains a binding site for GDP or GTP, which acts as a biological “switch” to regulate the transmission of a signal from the activated receptor.[9][10] The α subunit will dissociate and can then move in the plane of the membrane from the receptor to bind to downstream effectors to continue signal transmission and ultimately produce a cellular response.[9][10] Gq and Gi Family α SubunitsThe actions that G-proteins induce can be classified based on the sequence homology of α subunit (Gα) present.[9][11] The most well-known are referred to as Gi, Gs, and Gq. The Gs and Gq proteins are stimulatory, while the Gi protein is inhibitory.[9][11] In addition, proteins are classified based on the signaling pathway that they regulate. For example, Gq proteins are seen in a signaling pathway that relies on phospholipase C enzymes, while Gs and Gi proteins are regulators of adenylate cyclase.[11] On this page, we will be focusing solely on the structures of the Gq and Gi proteins and their interactions with mast-cell receptors. Gαq and Gαi are proteins comprised of 359 amino acid residues, with varying sequences, that both contain a helical domain and a GTPase binding domain.[11] The GTPase binding domain is responsible for the hydrolysis of GTP as well as the binding of the β and γ subunits that form the trimeric protein structure. The helical domain contains six α helices, which are responsible for the binding of the G-protein to the coupled receptor.[11] The conformations of the G-proteins vary based on their association with a particular membrane receptor due to interactions between the amino acids in the N-terminus of the α subunit and the C-terminus of the receptor.[11]
Binding to the extracellular N-terminus domain triggers a transmembrane conformation change of MRGPRX2, which demonstrates a less significant change when compared to other class A GPCRs due to the surface level binding of the ligand to MRGPRX2.[4] Once ligand binding and the conformational change to the active state have taken place, the signal is relayed to the α-subunit of the heterotrimeric G-protein.[10] The α-subunit will then exchange a GDP for GTP to initiate the dissociation of the α, β, and γ subunits.[10] During this dissociation, the α-subunit is able to travel away from the receptor in the plane of the membrane to bind to downstream effectors to produce a cellular response.[10] Clinical Relevanceinitiates IgE-mediated anaphylactic reactions.[12] MRGPRX2-mediated anaphylactic responses occur more quickly than IgE-mediated responses, but the responses also tended to be more transient.[12] Common commercial drugs, like icatibant and cetrorelix, as well as neuromuscular blocking agents activate mast cells through the MRGPRX2 pathway. Many mutations also affect the actions of MRGPRX2. For example, a single residue mutation in sub-pocket 1 (Glu164Arg) prevented interactions between the receptor and ligands like C48/80.[12] In addition, single nucleotide polymorphisms (SNPs) have been linked to many variations of MRGPRX2 which predispose patients to hyperactivation of the receptors. Two of the most common SNPs are Asn62Thr which affects the cytoplasmic domain and Asn16His which affects the extracellular domain.[12] These mutations have been theorized to potentially protect patients from drug-induced mast cell degranulation and hypersensitivity reactions. Interestingly, within the MRGPRX2-mediated pathway, reaction frequencies differ. In the same patients, anaphylactic reactions can occur by both IgE-mediated and MRGPRX2-mediated pathways. The presence of both mechanisms within a patient may be responsible for cross-reactivity between drugs.[12] This has led to a hypothesis that certain drugs may interact with MRGPRX2 on different active sites within the receptor. In addition, studies have also led to hypotheses that the intracellular signaling pathways triggered by the binding of varying drugs may have different intracellular responses based on the site of binding. 3D StructuresSee Also
References
Student contributorsJoey Gareis Madeline Beck
| |||||||||||||
